VALR and MoonPay Announce Integration to Enhance Global Crypto Access
VALR, Africa's largest cryptocurrency exchange by trade volume, and MoonPay, the global leader in crypto payments, today announced their integration to streamline fiat on- and off-ramps for users in over 180 countries. This partnership enables VALR to support 34 fiat currencies, including KES (Kenyan Shilling), NGN (Nigerian Naira), IDR (Indonesian Rupiah), TRY (Turkish Lira), BRL (Brazilian Real), and TWD (Taiwan Dollar), across payment methods such as Credit and Debit Cards, Apple Pay, Google Pay, PayPal, and Venmo.
The integration strengthens VALR's mission to expand its global footprint and provide seamless access to cryptocurrencies like Bitcoin and stablecoins. With a user base exceeding 1.3 million and over 1,300 corporate and institutional clients, VALR continues to lead the development of a more inclusive global financial system.
'We are thrilled to partner with MoonPay to enhance our platform's accessibility for users worldwide,' said Farzam Ehsani, Co-Founder and CEO of VALR. 'This integration empowers our global community with efficient access to cryptocurrencies, aligning with VALR's vision of building a financial system that reflects the oneness of humanity.'
'We believe the future of money is crypto, and our goal is to make it easy for everyone to participate in this new digital economy,' said Ivan Soto-Wright, co-founder and CEO at MoonPay. 'Partnering with VALR to broaden access to stablecoins and other tokens is an exciting step toward our shared mission of global crypto adoption, empowering users in Africa and beyond to hold value on-chain.'
Founded in 2018 and headquartered in Johannesburg, VALR offers a comprehensive suite of crypto services, including Spot Trading, Futures, Staking, Lending, OTC Trading, VALR Pay, and a world-class API for businesses to build on and high-frequency traders. Licensed by South Africa's FSCA, with regulatory approvals in Europe and initial approval from Dubai's VARA, VALR has raised $55 million from investors such as Pantera Capital, Fidelity's F-Prime, and Coinbase Ventures. MoonPay, trusted by over 30 million users, provides end-to-end solutions to simplify crypto access across 180+ countries.
About VALR
VALR is Africa's largest cryptocurrency exchange by trade volume, serving over 1.3 million users and 1,300 corporate clients. Founded in 2018, VALR offers products including Spot Trading, Futures, Staking, Lending, OTC Trading, VALR Pay, and a world-class API for businesses to build on and high-frequency traders. Headquartered in Johannesburg, VALR is licensed by the FSCA in South Africa, with approvals in Europe and initial approval from Dubai's VARA. The company has raised $55 million from investors like Pantera Capital, Coinbase Ventures, and F-Prime. For more, visit valr.com
About MoonPay
MoonPay creates a world where you own your digital future, giving you control of your identity, money, property, and data.
We are the market leader in end-to-end solutions simplifying access to the crypto economy for 30M+ verified accounts across 180+ countries, and trusted by iconic global brands to power the creation and movement of digital value.
Contact
VALR
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 hours ago
- Yahoo
Claire's store in Pembrokeshire at risk of closing after administration update
The Claire's store in Haverfordwest is at risk of closing after the fashion accessories chain filed for administration. Claire's revealed on Wednesday (August 13) that it had filed a Notice of Intention to Appoint Administrators ("NOI"). Interpath later confirmed Will Wright and Chris Pole had been appointed joint administrators. The administrators are set to seek a potential rescue deal for the chain, which has seen sales tumble in the face of recent weak consumer demand. What happens when a company goes into administration? This all comes after the US-based Claire's group filed for Chapter 11 bankruptcy in a court in Delaware last week. It is the second time the group has declared bankruptcy, after first filing for the process in 2018. Chief executive of Claire's, Chris Cramer, said: 'This decision, while difficult, is part of our broader effort to protect the long-term value of Claire's across all markets. 'In the UK, taking this step will allow us to continue to trade the business while we explore the best possible path forward. "We are deeply grateful to our employees, partners and our customers during this challenging period.' The UK high street shops that no longer exist Claire's store in Haverfordwest at risk of closing Claire's currently has 306 stores across the UK and Ireland - 278 in the UK and 28 in Ireland, while it has more than 2,150 employees. All these stores and jobs are now at risk, following Wednesday's administration update. One of the UK's 278 stores now at risk is located in Haverfordwest (Unit 7 Riverside Quay, Haverfordwest, SA61 2LJ). Claire's has revealed that for now, all its UK and Ireland stores will remain open and staff will stay in their current positions. Interpath said Mr Wright and Mr Pole will be contacting all of Claire's employees in the UK and Ireland to 'provide further information about what the administration means for them'. RECOMMENDED READING: Poundland on future of its Pembrokeshire stores amid nationwide closures The major high street brand stores closing in September from Poundland to M&S Full list of every Hobbycraft store closing down - See if your local is shutting Mr Wright, UK chief executive at Interpath, said: 'Claire's has long been a popular brand across the UK, known not only for its trend-led accessories but also as the go-to destination for ear piercing. 'Over the coming weeks, we will endeavour to continue to operate all stores as a going concern for as long as we can, while we assess options for the company. 'This includes exploring the possibility of a sale which would secure a future for this well-loved brand.'
Yahoo
2 days ago
- Yahoo
Potbelly's Q2 Earnings Call: Our Top 5 Analyst Questions
Potbelly's second quarter was marked by continued same-store sales growth, strong digital engagement, and accelerated shop expansion, leading to a favorable market response. Management cited menu innovation, including the introduction of the Prime Rib Steak sandwich, and enhanced digital channels as key contributors to increased traffic and transaction values. CEO Bob Wright highlighted the impact of Potbelly's 'five-pillar operating strategy' and credited the team's execution, stating, 'Our menu innovation and digital investments are driving profitable traffic growth.' Is now the time to buy PBPB? Find out in our full research report (it's free). Potbelly (PBPB) Q2 CY2025 Highlights: Revenue: $123.7 million vs analyst estimates of $122.6 million (3.4% year-on-year growth, 0.9% beat) Adjusted EPS: $0.09 vs analyst estimates of $0.09 (in line) Adjusted EBITDA: $9.63 million vs analyst estimates of $9.19 million (7.8% margin, 4.9% beat) EBITDA guidance for the full year is $34.5 million at the midpoint, above analyst estimates of $33.76 million Operating Margin: 3.4%, in line with the same quarter last year Locations: 440 at quarter end, up from 425 in the same quarter last year Same-Store Sales rose 3.2% year on year (0.4% in the same quarter last year) Market Capitalization: $388.8 million While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Our Top 5 Analyst Questions From Potbelly's Q2 Earnings Call Todd Brooks (The Benchmark Company) asked about the timeline for realizing the pipeline of over 360 franchise shop commitments. CEO Robert Wright explained that while some agreements allow up to eight years for development, incentives encourage earlier openings, and multi-unit deals can result in multiple openings per year. Brooks (The Benchmark Company) also questioned the balance between corporate and franchise expansion. Wright said Potbelly will selectively pursue company-operated shop openings to densify key markets without hindering franchise growth, emphasizing that company units will focus on markets with strong margins and lower construction costs. Jeremy Hamblin (Craig-Hallum Capital Group) inquired about the components of same-store sales growth and menu pricing. CFO Steve Cirulis detailed that sales gains were split between transaction increases and higher average checks, with pricing contributing a modest portion and mix effects slightly negative. Hamblin (Craig-Hallum Capital Group) sought clarity on upcoming menu innovation and the timeline for new launches. Wright confirmed ongoing tests of new items, guided by customer research, but refrained from specifying launch details until tests are complete. Mark Smith (Lake Street Capital) asked about returns from remodeled shops and prototype updates. Wright shared that early results from remodels and new shop designs are positive, with ongoing efforts to reduce build costs and enhance shop performance, though specific return data is still being gathered. Catalysts in Upcoming Quarters In the coming quarters, our analysts will focus on (1) the pace and quality of new shop openings from Potbelly's franchise and corporate pipelines, (2) measurable lift from menu innovation and digital enhancements, and (3) early returns from shop remodels and prototype updates. We will also monitor commodity cost trends and consumer behavior, especially regarding digital sales and value offerings. Potbelly currently trades at $12.85, up from $11.53 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it's free). Our Favorite Stocks Right Now Donald Trump's April 2025 "Liberation Day" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities. The smart money is already positioning for the next leg up. Don't miss out on the recovery - check out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
3 days ago
- Business Wire
Neurogene Reports Second Quarter 2025 Financial Results and Highlights Recent Updates
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced second quarter 2025 financial results and highlighted recent corporate updates. 'In the first half of 2025, we made significant progress in our NGN-401 program for Rett syndrome. We completed dosing of the last five participants in the Phase 1/2 trial and received written agreement from the U.S. FDA on the key elements of the Embolden™ registrational trial, in which we have already begun initiation activities,' stated Rachel McMinn, Ph.D., Founder and Chief Executive Officer of Neurogene. 'We are pleased to be moving forward with Embolden, which was purposefully and rigorously designed to differentiate NGN-401 by evaluating participants as young as three years of age with a primary endpoint that incorporates measures that KOLs, caregivers and payors believe to be clinically meaningful. Our previously announced reallocation of capital provides us runway into early 2028, enabling us to focus our resources on advancement of this potential therapy for the patients and families who urgently need new treatment options.' Dr. McMinn continued, 'In leveraging the continual dialogue under the START program, the FDA encouraged the analysis of the Embolden primary endpoint to remain at 12 months as the basis for full approval, noting that a 6-month endpoint may not be considered clinically meaningful. In further maintaining the rigorous design of the Embolden trial, we are electing to dose the last planned participant from the Phase 1/2 trial as part of the registrational Embolden trial and add one more participant to complete the proposed sample size at 20 patients.' Second Quarter 2025 and Recent Highlights, and Anticipated Milestones NGN-401 Gene Therapy for Treatment of Rett Syndrome Received written agreement from the U.S. Food and Drug Administration (FDA) on key elements of the Embolden registrational trial of NGN-401 and refined the sample size to propose 20 participants Initiated Embolden clinical trial activities to support the conversion of the Phase 1/2 trial to a registrational trial Completed enrollment in the Phase 1/2 trial, with the last 5 additional participants dosed in the first half of 2025 Remains on track to report updated clinical efficacy and safety data from the Phase 1/2 trial in the second half of 2025 Presented at scientific conferences the hemophagocytic lymphohistiocytosis (HLH) monitoring and treatment algorithm incorporated into the NGN-401 clinical trial, which has been acknowledged as valuable information by the Rett syndrome and gene therapy communities There has been no evidence of HLH/hyperinflammatory syndrome in any NGN-401 trial participant at the 1E15 vg dose level, as of the date of this press release Upcoming Events Stifel Biotech Summer Summit: Management will participate in a fireside chat at 12:00 p.m. ET on August 12 (not webcast) H.C. Wainwright Annual Global Investment Conference: Management will participate in a fireside chat at 2:30 p.m. ET on September 8 and participate in 1x1 meetings Second Quarter 2025 Financial Results Cash, Cash Equivalents and Short-Term Investments: Cash, cash equivalents and short-term investments as of June 30, 2025 were $274.5 million. We currently expect cash, cash equivalents and short-term investments to fund planned operations into early 2028. Research & Development (R&D) Expenses: R&D expenses were $19.4 million for the three months June 30, 2025 compared to $15.7 million for the three months ended June 30, 2024. The increase in R&D expenses for the three months ended June 30, 2025 was primarily driven by an increase in Rett syndrome clinical trial costs and employee-related expenses due to an increase in R&D headcount. General & Administrative (G&A) Expenses: G&A expenses were $6.7 million for the three months ended June 30, 2025 compared to $5.3 million for the three months ended June 30, 2024. The increase in G&A expenses for the three months ended June 30, 2025 was primarily driven by an increase in employee-related expenses due to an increase in stock-based compensation, headcount and other corporate expenses. Net Loss: Net loss was $22.0 million for the three months ended June 30, 2025 compared to $18.5 million for the three months ended June 30, 2024. About Neurogene The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. This includes selecting a delivery approach to maximize distribution to target tissues and designing products to maximize potency and purity for an optimized efficacy and safety profile. The Company's novel and proprietary EXACT™ transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. Neurogene has constructed a state-of-the-art gene therapy manufacturing facility in Houston, Texas. CGMP production of NGN-401 was conducted in this facility and will support pivotal clinical development activities. For more information, visit About NGN-401 NGN-401 is an investigational AAV9 gene therapy being developed as a one-time treatment for Rett syndrome. It is the first clinical candidate to deliver the full-length human MECP2 gene under the control of Neurogene's EXACT™ transgene regulation technology. EXACT technology is an important advancement in gene therapy for Rett syndrome, specifically because the disorder requires a treatment approach that enables targeted levels of MECP2 transgene expression without causing overexpression-related toxic effects associated with conventional gene therapy. NGN-401 was selected by the U.S. Food and Drug Administration (FDA) for its START Pilot Program and has also received Regenerative Medicine Advance Therapy (RMAT) designation, orphan drug designation, Fast Track designation and rare pediatric designation from the FDA. Neurogene was previously granted an INTERACT meeting with the FDA regarding the EXACT technology. NGN-401 also received Priority Medicines (PRIME) designation, orphan designation and advanced therapy medicinal product designation from the European Medicines Agency (EMA) and the Innovative Licensing and Application Pathway (ILAP) designation from the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA). Cautionary Note Regarding Forward-Looking Statements Statements in this press release are made as of the date of this press release. Neurogene does not undertake any obligation to make any updates to these statements to reflect events that occur or circumstances that arise after the date of this press release, except as may be required under applicable U.S. securities law. Statements in this press release which are not historical in nature are intended to be, and hereby are identified as, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current expectations and beliefs of the management of Neurogene, as well as assumptions made by, and information currently available to, management of Neurogene, including, but not limited to, statements regarding: the therapeutic potential and utility, efficacy and clinical benefits of NGN-401; trial designs, clinical development plans and timing for NGN-401, including elements of the registrational clinical study trial design subject to final approval of the FDA, such as the proposed number of participants in the Embolden trial, and the timing of the conversion of the NGN-401 Phase 1/2 clinical trial to a registrational clinical trial, anticipated timing of additional updates for the Embolden registrational trial of NGN-401 for Rett syndrome; expected timing for additional interim data from the Company's NGN-401 Phase 1/2 trial for Rett Syndrome, expected future interactions with or positions of the FDA; and the time period over which existing cash resources may be sufficient to fund the Company's operations. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as 'may,' 'will,' 'should,' 'would,' 'expect,' 'anticipate,' 'plan,' 'likely,' 'believe,' 'estimate,' 'project,' 'intend,' 'on track,' and other similar expressions or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Forward-looking statements are based on current beliefs and assumptions that are subject to risks, uncertainties and assumptions that are difficult to predict with regard to timing, extent, likelihood, and degree of occurrence, which could cause actual results to differ materially from anticipated results and many of which are outside of Neurogene's control. Such risks, uncertainties and assumptions include, among other things: the expected timing of additional results from the NGN-401 clinical trial; the potential for negative impacts to participants in the Phase 1/2 clinical trial of NGN-401 for the treatment of Rett syndrome; the risk that the Company may not be able to report data on the predicted timeline; risks related to the Company's ability to obtain regulatory approval for, and ultimately commercialize, its product candidates, including NGN-401; risks related to timing of initiating the Embolden trial of NGN-401 for Rett syndrome; and other risks and uncertainties identified under the heading "Risk Factors" included in Neurogene's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed with the Securities and Exchange Commission ('SEC') on August 11, 2025, and other filings that the Company has made and may make with the SEC in the future. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that the contemplated results of any such forward-looking statements will be achieved. Forward-looking statements in this communication speak only as of the day they are made and are qualified in their entirety by reference to the cautionary statements herein. Except as required by applicable law, Neurogene undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. This communication contains hyperlinks to information that is not deemed to be incorporated by reference into this communication. - Financial Tables Follow - Neurogene Inc. Condensed Consolidated Statements of Operations (In thousands of U.S. dollars, except share information) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Revenue under licensing agreements — 925 — 925 Operating expenses: Research and development expenses 19,366 15,744 37,131 29,285 General and administrative expenses 6,715 5,315 14,869 10,553 Total operating expenses 26,081 21,059 52,000 39,838 Loss from operations (26,081 ) (20,134 ) (52,000 ) (38,913 ) Other income, net 4,065 1,642 7,337 3,500 Net loss $ (22,016 ) $ (18,492 ) $ (44,663 ) $ (35,413 ) Per share information: Net loss per share, basic and diluted $ (1.05 ) $ (1.09 ) $ (2.12 ) $ (2.09 ) Weighted-average shares of common stock outstanding, basic and diluted 21,055,378 16,941,524 16,922,630 Expand
